Overview
- Q4 2025 Rytelo net revenue was $48 million as demand rose 9% quarter over quarter and prescribing accounts increased 13% to about 1,300.
- Management issued 2026 operating expense guidance of $230–$240 million, reflecting lower spending after a December 2025 restructuring.
- Geron reported roughly $400 million in cash and marketable securities with access to an additional $125 million under an amended loan facility through July 30, 2026.
- Commercial efforts center on an estimated 8,000 eligible second-line, lower-risk MDS patients in the U.S., with growth expected to be weighted to the back half of 2026.
- The company backs 10+ investigator-sponsored studies and real-world evidence efforts, and anticipates the fully enrolled IMpactMF trial to hit its interim trigger in H2 2026.